Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8794157 | Ophthalmology | 2018 | 14 Pages |
Abstract
Modulating conjunctival wound healing has the potential to improve outcomes after glaucoma filtration surgery and for several ocular disorders, including ocular cicatrial pemphigoid, vernal keratoconjunctivitis, and pterygium. Although anti-inflammatories and antimetabolites have been used with success, these nonspecific agents are not without their complications. The search for novel and more targeted means to control conjunctival fibrosis without such limitations has brought much attention to the regulation of fibroblast proliferation, differentiation, extracellular matrix production, and apoptosis. This review provides an update on where we stand with current antifibrotic agents and outlines the strategies that novel agents use, as they evolve from the bench to the bedside.
Keywords
TGF-βGFSSPARCMitomycin CECMCTGFMMCOCP5 fluorouracil5-FUMMPPI3Ktissue inhibitor of matrix metalloproteinaseTransforming growth factor βglaucoma filtration surgeryTIMPVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Connective tissue growth factorphosphoinositide 3-kinaseExtracellular matrixmatrix metalloproteinaseVKCsecreted protein acidic and rich in cysteineVernal keratoconjunctivitis
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Mark BMedSci (Hons I), MBBS, Ushasree PhD, Andrew PhD, FRANZCO,